{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:12:40Z","timestamp":1789560760430,"version":"build-2803163510"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>France reports markedly lower adult attention-deficit\/hyperactivity disorder (ADHD) medication use than other high-income countries despite similar prevalence. Methylphenidate is the predominant ADHD medication dispensed in France, accounting for the large majority of stimulant prescriptions in adults. Until recently, methylphenidate initiation was restricted to hospital specialists and largely excluded adult indications. Regulatory changes between 2021 and 2023 expanded adult access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Examine national trends in adult methylphenidate dispensing in France and quantify the impact of the November 2021 regulatory reform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nationwide retrospective cohort study using the French National Health Data System (SNDS), including adults (\u226518 years) with at least one community pharmacy dispensation of methylphenidate between January 2015 and December 2024. Weekly population-standardised dispensing rates were analysed using interrupted time-series models (quasi-Poisson) to estimate level and trend changes, stratified by sex and prescriber specialty. A secondary analysis examined incident treatment initiation to distinguish new users from individuals continuing pre-existing therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Between 2015 and 2024, a total of 195 393 adults received methylphenidate. Before the reform, weekly dispensing grew gradually (~0.2% per week). At reform implementation, an immediate 10.9% level increase occurred, followed by a sustained acceleration (~0.7% per week), largely driven by new treatment initiations. Similar patterns were seen in both sexes, though the immediate increase was greater for dispensing attributed to psychiatrists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The November 2021 reform was associated with a rapid and sustained expansion of adult methylphenidate use over the 3 years following the reform, primarily through increased treatment initiation, suggesting that prior regulatory constraints largely explained historically low treatment rates. Longer follow-up will be needed to assess whether this trajectory is maintained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Regulatory changes expanding ADHD treatment access may produce rapid prescribing increases, requiring adequate specialist capacity and stimulant use monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2026-302693","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:00:11Z","timestamp":1789560011000},"page":"e302693","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory reform and adult methylphenidate dispensing in France: a nationwide interrupted time-series study"],"prefix":"10.1136","volume":"29","author":[{"given":"Chlo\u00e9","family":"Saint-Dizier","sequence":"first","affiliation":[{"name":"Univ Lille, CHU Lille, ULR 2694-METRICS: \u00c9valuation des Technologies de Sant\u00e9 et des Pratiques M\u00e9dicales, Lille, France"},{"name":"F\u00e9d\u00e9ration R\u00e9gionale de Recherche en Psychiatrie et Sant\u00e9 Mentale des Hauts-de-France, Saint-Andr\u00e9-lez-Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Therribout","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique, H\u00f4pitaux Lariboisi\u00e8re-Fernand Widal, GHU APHP Nord, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 Paris-Cit\u00e9, INSERM, Optimisation th\u00e9rapeutique en neuropharmacologie OPTeN U1144, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Carton","sequence":"additional","affiliation":[{"name":"Pharmacology Department, INSERM UMR-S1172 Lille Neuroscience and Cognition, CHU Lille, Universit\u00e9 de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Icick","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Psychiatrie et de M\u00e9decine Addictologique, H\u00f4pitaux Lariboisi\u00e8re-Fernand Widal, GHU APHP Nord, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 Paris-Cit\u00e9, INSERM, Optimisation th\u00e9rapeutique en neuropharmacologie OPTeN U1144, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Mercier","sequence":"additional","affiliation":[{"name":"F\u00e9d\u00e9ration R\u00e9gionale de Recherche en Psychiatrie et Sant\u00e9 Mentale des Hauts-de-France, Saint-Andr\u00e9-lez-Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Caron","sequence":"additional","affiliation":[{"name":"EPSM des Flandres, Bailleul, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Bubrovszky","sequence":"additional","affiliation":[{"name":"Univ Lille, CHU Lille, ULR 2694-METRICS: \u00c9valuation des Technologies de Sant\u00e9 et des Pratiques M\u00e9dicales, Lille, France"},{"name":"F\u00e9d\u00e9ration R\u00e9gionale de Recherche en Psychiatrie et Sant\u00e9 Mentale des Hauts-de-France, Saint-Andr\u00e9-lez-Lille, France"},{"name":"EPSM de l\u2019Agglomeration Lilloise, Saint-Andr\u00e9-lez-Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aghil\u00e8s","family":"Hamroun","sequence":"additional","affiliation":[{"name":"Department of Public Health\u2013Epidemiology, Lille University Hospital Center, Lille University, Lille, France"},{"name":"UMR1167 RID-AGE, Pasteur Institute of Lille, Inserm, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"G\u00e9nin","sequence":"additional","affiliation":[{"name":"Univ Lille, CHU Lille, ULR 2694-METRICS: \u00c9valuation des Technologies de Sant\u00e9 et des Pratiques M\u00e9dicales, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1808","authenticated-orcid":false,"given":"Antoine","family":"Lamer","sequence":"additional","affiliation":[{"name":"Univ Lille, CHU Lille, ULR 2694-METRICS: \u00c9valuation des Technologies de Sant\u00e9 et des Pratiques M\u00e9dicales, Lille, France"},{"name":"F\u00e9d\u00e9ration R\u00e9gionale de Recherche en Psychiatrie et Sant\u00e9 Mentale des Hauts-de-France, Saint-Andr\u00e9-lez-Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026091605000601000_29.1.e302693.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1"},{"key":"2026091605000601000_29.1.e302693.2","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2024.1786","article-title":"Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis","volume":"67","author":"Popit","year":"2024","journal-title":"Eur Psychiatr"},{"key":"2026091605000601000_29.1.e302693.3","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21374"},{"key":"2026091605000601000_29.1.e302693.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1917069"},{"key":"2026091605000601000_29.1.e302693.5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S2215-0366(24)00360-2","article-title":"Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysis","volume":"12","author":"Ostinelli","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026091605000601000_29.1.e302693.6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2215-0366(25)00062-8","article-title":"Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"12","author":"Farhat","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026091605000601000_29.1.e302693.7","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2026091605000601000_29.1.e302693.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101780","article-title":"Attention-deficit\/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal study","volume":"58","author":"Chan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026091605000601000_29.1.e302693.9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.therap.2018.09.072","article-title":"French administrative health care database (SNDS): The value of its enrichment","volume":"74","author":"Scailteux","year":"2019","journal-title":"Therapie"},{"key":"2026091605000601000_29.1.e302693.10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.therap.2017.05.005","article-title":"Methylphenidate: Gender trends in adult and pediatric populations over a 7 year period","volume":"72","author":"Ehrhardt","year":"2017","journal-title":"Therapies"},{"key":"2026091605000601000_29.1.e302693.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115449"},{"key":"2026091605000601000_29.1.e302693.12","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14207338","article-title":"Global Trends in ADHD Medication Use: Multiple Contexts and Rising Concerns-A Narrative Review","volume":"14","author":"Rzeszutek","year":"2025","journal-title":"J Clin Med"},{"key":"2026091605000601000_29.1.e302693.13","first-page":"467","article-title":"ADHD Diagnostic Trends: Increased Recognition or Overdiagnosis?","volume":"119","author":"Abdelnour","year":"2022","journal-title":"Mo Med"},{"key":"2026091605000601000_29.1.e302693.14","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1612785","article-title":"Misuse and diversion of stimulant medications prescribed for the treatment of ADHD: a systematic review","volume":"16","author":"Forrest","year":"2025","journal-title":"Front Psychiatry"},{"key":"2026091605000601000_29.1.e302693.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-024-06199-9","article-title":"Nationwide trends in the use of ADHD medications in the period 2006-2022: a study from the Norwegian prescription database","volume":"24","author":"Hartz","year":"2024","journal-title":"BMC Psychiatry"},{"key":"2026091605000601000_29.1.e302693.16","doi-asserted-by":"publisher","DOI":"10.1111\/JCPP.13987"},{"key":"2026091605000601000_29.1.e302693.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101556","article-title":"Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study","volume":"61","author":"Li","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"2026091605000601000_29.1.e302693.18","doi-asserted-by":"crossref","first-page":"103205","DOI":"10.1016\/j.ajp.2022.103205","article-title":"Gender-based differences in prevalence and effects of ADHD in adults: A systematic review","volume":"75","author":"Faheem","year":"2022","journal-title":"Asian J Psychiatr"},{"key":"2026091605000601000_29.1.e302693.19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-006196","article-title":"The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China","volume":"6","author":"Zhang","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2026091605000601000_29.1.e302693.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2021-013910"},{"key":"2026091605000601000_29.1.e302693.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040232","article-title":"The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension: interrupted time-series analysis","volume":"4","author":"Fretheim","year":"2007","journal-title":"PLoS Med"},{"key":"2026091605000601000_29.1.e302693.22","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/1087054720905664","article-title":"ADHD Diagnosis and Drug Use Estimates in France: A Case for Using Health Care Insurance Data","volume":"25","author":"Ponnou","year":"2021","journal-title":"J Atten Disord"},{"key":"2026091605000601000_29.1.e302693.23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/00048674231170556","article-title":"Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit\/hyperactivity disorder: An interrupted time-series analysis","volume":"57","author":"Bruno","year":"2023","journal-title":"Aust N Z J Psychiatry"},{"key":"2026091605000601000_29.1.e302693.24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.encep.2018.05.008","article-title":"Supervised off-label prescribing of methylphenidate in adult ADHD","volume":"45","author":"Carton","year":"2019","journal-title":"Encephale"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2026-302693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:00:14Z","timestamp":1789560014000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2026-302693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjment-2026-302693"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2026-302693","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}